One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.
本公开的一个实施方案是由式 I 代表的化合物或其药学上可接受的盐。式 I 中的变量在本文中定义。式 I 的化合物是选择性 MAP4K1 抑制剂,可用于治疗受益于 MAP4K1 活性控制的受试者的疾病或失调。
[EN] SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS<br/>[FR] AZAHÉTÉROCYCLES BICYCLIQUES SUBSTITUÉS ET ANALOGUES COMME MODULATEURS DE LA SIRTUINE
申请人:GLAXOSMITHKLINE LLC
公开号:WO2013059587A9
公开(公告)日:2014-10-23
SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
申请人:GlaxoSmithKline LLC
公开号:EP2768509B1
公开(公告)日:2017-03-22
US9957271B2
申请人:——
公开号:US9957271B2
公开(公告)日:2018-05-01
[EN] MAP4K1 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K1
申请人:BLUEPRINT MEDICINES CORP
公开号:WO2021146370A1
公开(公告)日:2021-07-22
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.